Work

A phase I study of BAY 43–9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC)

Year: 2005

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2005.23.16_suppl.3067

Authors: A. A. Adjei, S. Mandrekar, R. S. Marks, L. J. Hanson, D. Aranguren, J. R. Jett, R. Simantov, B. Schwartz, G. A. Croghan

Institution: Mayo Clinic

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2336431470

Cites:

Cited by: 34

Related to: 10